Literature DB >> 10597065

The continuing challenge of Fournier's gangrene in the 1990s.

J N Olsofka1, E H Carrillo, D A Spain, H C Polk.   

Abstract

Fournier's disease is a potentially fatal acute, gangrenous infection of the scrotum, penis, or perineum associated with a synergistic bacterial infection of the subcutaneous fat and superficial fascia. Thrombosis of small subcutaneous arterioles with resultant ischemia contributes to the rapid extension of the infection. During a 12-year period, the clinical and operative records of 14 patients with Fournier's gangrene were analyzed. All patients were treated with broad spectrum antibiotics and serial surgical debridements. Nine patients had polymicrobial isolates from the initial wound culture; two patients had Group A Streptococcus species as the sole isolate. The etiology of the infection was identified in 12 patients. Five patients died for an overall mortality of 38 per cent. The mean age of survivors was 51 years compared with 75 years for nonsurvivors (P<0.05). The last six patients in this series survived. The mean hospital stay was 29 days. Four patients (31%) had a prior history of diabetes; however, 11 patients (85%) had elevated serum glucose levels (>120 mg/dL) on admission. All patients were hypoalbuminemic on admission. Survivors had an average serum creatinine on admission of 1.28 mg/dL compared with 3.1 mg/dL for nonsurvivors. Although supportive care is required in these patients, the mainstay for treatment of Fournier's gangrene entails an aggressive approach with frequent and extensive soft tissue debridements to control the invasive nature of the infection with delayed wound coverage once the infection has been controlled. Elderly patients with evidence of renal dysfunction on admission have a poor prognosis despite aggressive therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10597065

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  8 in total

1.  Comparison of Diverting Colostomy and Bowel Management Catheter Applications in Fournier Gangrene Cases Requiring Fecal Diversion.

Authors:  Ismail Cem Eray; Omer Alabaz; Atilgan Tolga Akcam; Abdullah Ulku; Cem Kaan Parsak; Gurhan Sakman; Gulsah Seydaoglu
Journal:  Indian J Surg       Date:  2013-01-27       Impact factor: 0.656

2.  Prognostic Factors for Fournier's Gangrene; A 10-year Experience in Southeastern Iran.

Authors:  Amene Sabzi Sarvestani; Mehdi Zamiri; Mehdi Sabouri
Journal:  Bull Emerg Trauma       Date:  2013-07

3.  A life-threatening infection: Fournier's gangrene.

Authors:  Irfan Huseyin Atakan; Mustafa Kaplan; Esat Kaya; Tevfik Aktoz; Osman Inci
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

4.  Fournier's gangrene: our experience with 50 patients and analysis of factors affecting mortality.

Authors:  El Bachir Benjelloun; Tarik Souiki; Nadia Yakla; Abdelmalek Ousadden; Khalid Mazaz; Abdellatif Louchi; Nabil Kanjaa; Khalid Ait Taleb
Journal:  World J Emerg Surg       Date:  2013-04-01       Impact factor: 5.469

5.  Treatment of Fournier's Gangrene with Combination of Vacuum-Assisted Closure Therapy, Hyperbaric Oxygen Therapy, and Protective Colostomy.

Authors:  Giovanni Zagli; Giovanni Cianchi; Sara Degl'innocenti; Jessyca Parodo; Lorenzo Bonetti; Paolo Prosperi; Adriano Peris
Journal:  Case Rep Anesthesiol       Date:  2012-01-23

6.  A Case of Acute Aortoiliac Occlusive Disease Presenting as Cauda Equina Syndrome and Fournier´s Gangrene.

Authors:  Rosalba Paone; Pekka Romsi
Journal:  Case Rep Surg       Date:  2019-04-17

7.  Fournier's Gangrene: validation of the severity index.

Authors:  Ahmed Itaimi; Wissem Triki; Imed Abbassi; Karim Ayed; Oussama Baraket; Sami Bouchoucha
Journal:  Tunis Med       Date:  2022 fevrier

8.  Management of Fournier's gangrene: review of 45 cases.

Authors:  Mahmut Basoglu; Isa Ozbey; Sabri Selcuk Atamanalp; Mehmet Ilhan Yildirgan; Bulent Aydinli; Ozkan Polat; Gurkan Ozturk; Kemal Peker; Omer Onbas; Durkaya Oren
Journal:  Surg Today       Date:  2007-06-26       Impact factor: 2.540

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.